Alopecia, Androgenetic, Healthy
Conditions
Brief summary
Androgenetic alopecia is a chronic pathology affecting approximately 50% of men at 50 years old and is characterized by a progressive miniaturization of the hair follicle leading to a localized baldness. Although it has been shown that testosterone metabolism plays a central role in this pathology, targeting this biological pathway is not fully efficient to treat androgenetic alopecia, suggesting that other factors are involved, notably factors linked to the perifollicular environment. Moreover, the very specific pattern of androgenetic alopecia is not yet fully understood: the occipital and lower temporal areas of the scalp are always preserved. Once the hair follicle has disappeared, it is not possible to make it grow back, it is then important to provide a treatment that slows down the progression of androgenetic alopecia at the earliest stage of the pathology, and that specifically targets the affected area. The aim of this study is to better understand androgenetic alopecia pathophysiology by a multi-omic approaches and biometrological analysis, in the same study, on the local ecosystem of bald scalp areas and non-bald scalp areas of adult with androgenetic alopecia, compared to scalp of adult without androgenetic alopecia.
Interventions
Measurements will be taken from the scalp: on the vertex and occiput areas.
OTHERBiological sampling
Samples will be taken from the scalp: on the vertex and occiput areas.
Sponsors
Pierre Fabre Dermo Cosmetique
Study design
Allocation
NA
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
30 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
Selection criteria: Criteria related to the population: * Male * Subject aged between 30 and 50 years included Criteria related to the scalp condition: * Subject with hair length over 3 cm * Subject presenting a negative pull test result Specific for non-AGA group: • Non-alopecic men with full head of hair with uniform scalp coverage (homogeneous hair density on the vertex, occiput, left and right parietal areas) Specific for AGA group: • Androgenetic alopecic men with progressive AGA for more than 5 years: stage between III to IV included according to the Hamilton's classification modified by Norwood Non-selection criteria: Criteria related to the population: * Subject having received on study areas artificial UV exposure, excessive or prolonged exposure to natural sunlight within 2 months before the selection visit * Subjects with frizzy hair Criteria related to diseases: * Subject having neoplastic disease (history of disease or disease on-going) * Subject having severe acute progressive disease (infectious syndromes, inflammatory, COVID-19, acute fever...) occurred within the last 3 months before the selection visit liable to interfere with the study assessments * Subject with iron deficiency on-going, not treated or treated for less than 3 months before the selection visit * Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the investigator hazardous for the subject or incompatible with the study requirements Specific for non-AGA group: * Subject with any type of alopecia * Subject with family history of androgenetic alopecia in the father with stage ≥ III according to the Hamilton's classification modified by Norwood Specific for AGA group: • Subject with non-androgenetic alopecia (Cicatricial alopecia, Alopecia aerata...) Criteria related to procedures, treatments, products and/or hair care routine: * Radiotherapy, chemotherapy * Scalp surgery * Systematic or local androgenetic alopecia treatment or product, taken or applied for more than 4 consecutive weeks during the last 6 months before the selection visit * Any following hair care within the last 3 months before the selection visit: dyeing, bleaching, perm * Systemic or local non-steroidal anti-inflammatory drug taken or applied on the scalp for more than 1 week during the last month (systematic NSAIDs) or 2 weeks (local NSAIDs) before the selection visit Non-inclusion criteria: Criteria related to the population: * Subject having received on study areas artificial UV exposure, excessive or prolonged exposure to natural sunlight between selection and inclusion visit Criteria related to the disease: • Subject with any adverse event occurring between selection and inclusion visit liable to interfere with the study assessments Criteria related to treatments and/or products: • Any procedures, treatments, products and/or hair care taken, applied or performed between selection and inclusion visit liable to interfere with the study assessments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipidomic profiles by sampling method (swabs) | baseline (Visit 1- Day 1) |
| Cutaneous pH measurement | baseline (Visit 1- Day 1) |
| Sebum quantification : by Lipidic Index (LI) - Sebumeter® | baseline (Visit 1- Day 1) |
| Skin elasticity : by determination of the mechanical property of the skin with a biomechanical device | baseline (Visit 1- Day 1) |
| Cutaneous hydratation : by Hydratation Index (IH) - DermaLab® | baseline (Visit 1- Day 1) |
| Cutaneous barrier integrity : by Trans-Epidermal Water Loss (TEWL) - Vapometer® | baseline (Visit 1- Day 1) |
| Lipidomic profile by mass spectroscopy (in-vivo measurements) | baseline (Visit 1- Day 1) |
| Lipidomic profile by sampling method (absorbent paper) | baseline (Visit 1- Day 1) |
| Microbiota analysis by sampling method (hair follicles) | baseline (Visit 1- Day 1) |
| Microbiota analysis by sampling method (swabs) | baseline (Visit 1- Day 1) |
| Metabolite analysis by sampling method (hair follicles) | baseline (Visit 1- Day 1) |
| Transcriptomic analysis by sampling method (hair follicles) | baseline (Visit 1- Day 1) |
| Transcriptomic analysis by sampling method (swabs) | baseline (Visit 1- Day 1) |
Countries
France
Outcome results
None listed